3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
8
Terminated
5
Recruiting
5
Withdrawn
1
Unknown
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
4
Prostatic Neoplasms, Castration-Resistant
2
Neoplasms
2
Neoplasm Metastasis
1
Breast Neoplasms
1
Interventions
Radiosurgery
7
Oxaliplatin
7
Docetaxel
7
Paclitaxel
5
Fluorouracil
5
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Carboplatin
4
Capecitabine
4
Trastuzumab
3
Radiotherapy
3
Radiation
3
Leucovorin
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
Cetuximab
3
Bevacizumab
3
spartalizumab
2
sipuleucel-T
2
repotrectinib
2
pembrolizumab
2
pazopanib
2
orteronel
2
fludarabine
2
atezolizumab
2
aldesleukin
2
Temozolomide
2
Surveys and Questionnaires
2
Sunitinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasm Metastasis
×
enzalutamide
×
Clear all
NCT02929576
2018-10-22
ENDEAR
Pfizer
Phase 3
Withdrawn